Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1764013 · FYE Mar 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $38.90Day −2.97%Mkt cap $8.0B1Y +132.1%Off 52W high −5.7%Vol (1Y) 62.1%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,653 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest8.6% of sh out |
| Days to cover16.7d |
| 13F net flow (QoQ)+1.54% |
| Top-10 13F concentration57.8% |
| Next report (est.)2026-08-19 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$505.6M |
| ROE−64.8% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+53.0% |
| 1Y+132.1% |
| 3Y+72.7% |
| 5Y+260.5% |
| Since incept. (ann.)+14.4% |
Total return through 2026-07-28 · series begins 2019-12-19. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)62.1% |
| Ann. volatility (3Y)78.8% |
| Sharpe (1Y)1.68 |
| Sharpe (3Y)0.56 |
| Max drawdown (1Y)−17.2% |
| Max drawdown (3Y)−69.9% |
| Beta (3Y vs SPY)0.41 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 16.9M | $421M | 8.25% | −0.3% |
| Deep Track Capital, LP | 11.5M | $286M | 5.61% | +0.0% |
| BlackRock, Inc. | 6.6M | $163M | 3.20% | +8.5% |
| BAKER BROS. ADVISORS LP | 5.5M | $136M | 2.66% | +0.0% |
| STATE STREET CORP | 4.5M | $113M | 2.21% | +19.8% |
| TCG Crossover Management, LLC | 4.5M | $111M | 2.17% | +168.4% |
| MORGAN STANLEY | 3.9M | $96M | 1.89% | −20.0% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.7M | $92M | 1.80% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2025-12-31 | 2026-02-06 | −$0.61 | — | — | — |
| 2025-09-30 | 2025-11-10 | −$0.73 | — | — | — |
| 2025-06-30 | 2025-08-11 | −$0.71 | — | — | — |
| 2024-12-31 | 2025-02-06 | −$0.76 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-19 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
